Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
Orna Therapeutics has raised $221.0M in total funding. The most recent round was Series B. The last funding was announced in August 2022.
Orna Therapeutics's investors include Bristol-Myers Squibb, Merck, Taiho Ventures, MPM Capital, F2 Ventures.
Orna Therapeutics is headquartered in Cambridge, United States.
Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
Orna Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Orna Therapeutics — Funding & Investors." VCBacked, August 16, 2022, https://www.vcbacked.co/company/orna-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). Orna Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/orna-therapeutics
{{cite web |title=Orna Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/orna-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated